Novartis dials down RNA research

Share this article:

Novartis is scaling down its push to develop RNA therapies. BioCentury reports that the drugmaker plans to “maintain a small group in the field and will look into partnering opportunities” but will “significantly reduce” its internal focus.

According to BioCentury, the drugmaker said RNA treatments look to be a narrow field and that the company expects to lay off some of the 26 employees dedicated to RNA research.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.